IN2015DN03921A - - Google Patents

Info

Publication number: IN2015DN03921A
Authority: IN; India
Prior art keywords: release pharmaceutical; pharmaceutical formulations; formulations; oprozomib; tablets
Prior art date: 2012-10-24

Application number

Other languages

English (en)

Inventor

Mouhannad Jumaa

Tony Muchamuel

Naveen Bejugam

Hansen Wong

Christopher J Kirk

Rahul Vishram Manek

Sanjeev Sharma

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-24

Filing date

2013-10-24

Publication date

2015-10-02

2013-10-24 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2015-10-02 Publication of IN2015DN03921A publication Critical patent/IN2015DN03921A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IN3921DEN2015 2012-10-24 2013-10-24 IN2015DN03921A (el)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261717975P	2012-10-24	2012-10-24
US201261721244P	2012-11-01	2012-11-01
US201361793087P	2013-03-15	2013-03-15
PCT/US2013/066679 WO2014066681A1 (en)	2012-10-24	2013-10-24	Modified release formulations for oprozomib

Publications (1)

Publication Number	Publication Date
IN2015DN03921A true IN2015DN03921A (el)	2015-10-02

Family

ID=50485877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3921DEN2015 IN2015DN03921A (el)	2012-10-24	2013-10-24

Country Status (24)

Country	Link
US (2)	US9295708B2 (el)
EP (1)	EP2912025A4 (el)
JP (1)	JP6505604B2 (el)
KR (1)	KR20150070406A (el)
CN (1)	CN104968650A (el)
AP (1)	AP3681A (el)
AR (1)	AR093126A1 (el)
AU (1)	AU2013334258A1 (el)
BR (1)	BR112015008572A2 (el)
CA (1)	CA2888039A1 (el)
CL (1)	CL2015001085A1 (el)
CR (1)	CR20150266A (el)
EA (1)	EA201590797A1 (el)
HK (2)	HK1208222A1 (el)
IL (1)	IL238244A0 (el)
IN (1)	IN2015DN03921A (el)
MX (1)	MX2015005069A (el)
PE (1)	PE20151051A1 (el)
PH (1)	PH12015500823A1 (el)
SG (1)	SG11201502849XA (el)
TN (1)	TN2015000135A1 (el)
TW (1)	TW201422255A (el)
UY (1)	UY35091A (el)
WO (1)	WO2014066681A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2016204939A1 (en)	2015-06-19	2016-12-22	Biotie Therapies, Inc.	Controlled-release tozadenant formulations
CN105949279A (zh) *	2016-04-27	2016-09-21	浙江大学	蛋白酶体抑制剂Oprozomib及其类似物的制备方法
US10781192B2 (en) *	2016-06-29	2020-09-22	Kezar Life Sciences	Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
US20180078532A1 (en)	2016-09-21	2018-03-22	Amgen Inc.	Immediate release formulations for oprozomib
JP2018123119A (ja)	2016-12-14	2018-08-09	アムジエン・インコーポレーテツド	オプロゾミブのための胃内保持型の徐放性剤形、及びその調製プロセス
CN111108125A (zh)	2017-09-14	2020-05-05	葛兰素史密斯克莱知识产权发展有限公司	用于癌症的组合治疗
CN110357940A (zh) *	2019-08-02	2019-10-22	苏州艾和医药科技有限公司	奥普佐米合成工艺研究
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5126145A (en) *	1989-04-13	1992-06-30	Upsher Smith Laboratories Inc	Controlled release tablet containing water soluble medicament
JPH06199657A (ja) *	1992-12-10	1994-07-19	Sumitomo Pharmaceut Co Ltd	徐放性製剤
WO1998010779A1 (en)	1996-09-13	1998-03-19	New York University	Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) *	1999-03-25	2011-08-17	大塚製薬株式会社	シロスタゾール製剤
CN101671260A (zh) *	2001-02-12	2010-03-17	惠氏公司	制备o-去甲基-文拉法辛的方法
US8119154B2 (en) *	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
KR101274417B1 (ko) *	2005-11-09	2013-06-17	프로테올릭스, 인코퍼레이티드	효소 저해를 위한 화합물
JP5124286B2 (ja) *	2006-01-10	2013-01-23	キッセイ薬品工業株式会社	徐放性製剤およびその製造方法
WO2008140782A2 (en)	2007-05-10	2008-11-20	Proteolix, Inc.	Compounds for enzyme inhibition
SG185994A1 (en) *	2007-10-04	2012-12-28	Onyx Therapeutics Inc	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
TWI504598B (zh) *	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑

2013
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en active Application Filing
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
- 2015-09-10 HK HK15108858.7A patent/HK1208222A1/xx unknown
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
- 2016-03-31 HK HK16103699.0A patent/HK1215709A1/zh unknown

Also Published As

Publication number	Publication date
US20160213610A1 (en)	2016-07-28
HK1215709A1 (zh)	2016-09-09
BR112015008572A2 (pt)	2017-07-04
UY35091A (es)	2014-05-30
CR20150266A (es)	2015-08-14
WO2014066681A1 (en)	2014-05-01
PH12015500823A1 (en)	2015-06-22
AU2013334258A1 (en)	2015-04-30
JP2015535255A (ja)	2015-12-10
PE20151051A1 (es)	2015-08-03
EP2912025A1 (en)	2015-09-02
US20140113855A1 (en)	2014-04-24
CA2888039A1 (en)	2014-05-01
KR20150070406A (ko)	2015-06-24
CN104968650A (zh)	2015-10-07
JP6505604B2 (ja)	2019-04-24
MX2015005069A (es)	2015-07-17
HK1208222A1 (en)	2016-02-26
AP2015008387A0 (en)	2015-04-30
CL2015001085A1 (es)	2015-08-28
EA201590797A1 (ru)	2016-02-29
TW201422255A (zh)	2014-06-16
SG11201502849XA (en)	2015-05-28
US9295708B2 (en)	2016-03-29
AP3681A (en)	2016-04-19
EP2912025A4 (en)	2016-06-08
IL238244A0 (en)	2015-06-30
TN2015000135A1 (en)	2016-10-03
AR093126A1 (es)	2015-05-20

Publication	Publication Date	Title
IN2015DN03921A (el)	2015-10-02
SG10201810985XA (en)	2019-01-30	Tofacitinib oral sustained release dosage forms
IN2012DN06720A (el)	2015-10-23
EA201200937A1 (ru)	2013-02-28	Твердая лекарственная форма тикагрелора
MX2013006591A (es)	2013-11-04	Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MY165149A (en)	2018-02-28	Use of binders for manufacturing storage stable formulations
PH12012502083A1 (en)	2017-07-26	Manufacturing of active-free granules and tablets comprising the same
MY157673A (en)	2016-07-15	Pharmaceutical compositions comprising hydromorphone and naloxone
CY1118032T1 (el)	2017-05-17	Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
PH12012502082A1 (en)	2022-10-05	Combination of active loaded granules with additional actives
HK1218884A1 (zh)	2017-03-17	用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
PL3003383T3 (pl)	2019-04-30	Stała kompozycja do podawania doustnego zawierająca kwas ibandronowy lub jego farmaceutycznie dopuszczalną sól i witaminę d
MX2016006087A (es)	2016-08-12	Formulaciones de desintegracion rapida y metodos de uso.
EA201991359A1 (ru)	2020-03-13	Фармацевтические лекарственные формы
ZA201500411B (en)	2016-01-27	Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
EA201491477A1 (ru)	2015-02-27	Фармацевтические составы, содержащие флупиртин
MY159675A (en)	2017-01-13	Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
IN2015MU00907A (el)	2015-04-24
ES2422657A1 (es)	2013-09-12	Composición farmacéutica sólida de cilostazol
WO2014064711A3 (en)	2014-06-19	Methods of administering raltegravir and raltegravir compositions
TN2011000018A1 (en)	2012-09-05	Pharmaceutical formulations containing dopamine receptor ligands